Banner Health Issued Valley Fever Risk Warning
Officials cautioned Arizona residents about increased fungal infection risks during the monsoon season.
Updated on Sept. 26, 2026 in Asthma
Live Poll
Should residents in high-risk areas proactively request testing for local environmental diseases?
Banner Health has issued a public warning regarding Valley fever risks as monsoon storms heighten the potential for dust inhalation in Arizona. To address the endemic threat, Banner Urgent Care has implemented expanded diagnostic testing protocols.
Why it matters
Valley fever is caused by inhaling Coccidioides fungus spores from dry soil, making monsoon weather a critical risk factor for residents. Early detection through improved clinical protocols helps prevent unnecessary antibiotic prescriptions.
The CDC estimates the true annual burden of Valley fever is 206,000 to 360,000 cases, which is 10 to 18 times higher than the 20,000 cases typically reported annually. Officials report approximately 200 deaths per year, though estimates suggest the actual toll reaches 700 to 1,100.
The players
Banner Health
This is a non-profit health system based in Arizona that provides a wide range of medical services across several states.
Banner Urgent Care
This is the primary care division within Banner Health that manages walk-in patient diagnostics and acute illness screenings.
Anivive Lifesciences
This is a biotechnology company currently developing a vaccine for Valley fever, initially targeting canine populations before human application.
The details
Valley fever is a non-contagious fungal infection that individuals can only contract by inhaling spores spread by wind over large distances. Banner Urgent Care has responded by automatically testing patients presenting with pneumonia symptoms or red bumps on their shins.
Timeline
August 21, 2026: Banner Urgent Care announced expanded testing protocols.
September 24, 2026: The National Weather Service forecasted monsoon showers and thunderstorms.
The Big Picture
This response to the seasonal rise in infections occurs alongside the ongoing progression of the Anivive Lifesciences Valley fever vaccine development program. These efforts represent a shift toward long-term prevention for a disease that currently relies on diagnostic management.
Residents in endemic areas should remain aware that monsoon dust increases the likelihood of inhaling the fungus, especially when symptomatic. Patients seeking care for pneumonia or specific skin lesions at Banner facilities will now undergo automatic screening to facilitate earlier treatment.
The takeaway
Valley fever is not contagious, and those who have already had the infection develop a permanent immunity to it. Residents should minimize exposure to dust during high-wind events to reduce the risk of inhaling spores.
Further reading
Learn more about local respiratory health concerns on the Arizona Asthma section.
Source note: This article includes information reported by Arizona Public Media.
Live Poll
Should residents in high-risk areas proactively request testing for local environmental diseases?
